Latest Parkinson's disease Stories
EMERYVILLE, Calif., March 20, 2013 /PRNewswire/-- Adamas Pharmaceuticals, Inc. will present research results today from its Nurelin(TM )(amantadine HCl extended release capsules) program demonstrating the benefit of amantadine in traumatic brain injury (TBI) at the 65(th) American Academy of Neurology (AAN) Annual Meeting being held in San Diego, CA. Nurelin, a once-daily extended release formulation of amantadine intended for nighttime administration, is being evaluated in a Phase...
Data from a non-interventional, observational study of 76 patients presented at the 65th American Academy of Neurology Annual Meeting ATLANTA, March 19, 2013 /PRNewswire/ -- UCB today announced data from a non-interventional, observational study conducted in Germany that found that when Parkinson's disease (PD) patients were switched from an oral PD medication to Neupro(®) (Rotigotine Transdermal System), they reported improvements in pre-existing gastrointestinal (GI) symptoms....
The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology (AAN), March 16-23, 2013, in San Diego. For additional information, or to arrange an interview, please contact Karin Eskenazi at 212-342-0508 or ket2116@columbia.edu, or Christina Stolfo at 212-305-5587 or chs9135@nyp.org ORAL PRESENTATIONS Deoxypyrimidine Monophosphates Treatment for Thymidine Kinase 2...
LONDON, March 18, 2013 /PRNewswire/ -- The Cure Parkinson's Trust, a charity founded by four people with Parkinson's disease, which is dedicated to finding, facilitating and funding work towards a cure, today welcomes Kenneth Mulvany to the charity as Chairman. Ken Mulvany is an entrepreneur and healthcare industry veteran and brings more than 15 years of business leadership and experience to The Cure Parkinson's Trust. Ken was previously CEO of Proximagen, a UK-based...
SAN DIEGO, March 14, 2013 /PRNewswire-USNewswire/ -- Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are...
NESS ZIONA, Israel, March 4, 2013 /PRNewswire/ -- NeuroDerm [http://www.neuroderm.com ], Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously sub-cutaneously through a patch pump. It is designed to provide steady levodopa blood levels for the reduction of motor complications in Parkinson's...
BRONX, N.Y., March 3, 2013 /PRNewswire-USNewswire/ -- Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells. The study, which published online today in the journal Nature Neuroscience, could also open up treatment possibilities for both familial Parkinson's and the more common form of Parkinson's that is not inherited. (Logo:...
SUNNYVALE, Calif., Feb. 28, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced that Dr. John W. Commissiong, Chief Scientific Officer, will be presenting data generated in six hydroxydopamine (6-OHDA) rodent models of Parkinson's disease at the 15(th) Annual Meeting...
-- $53 million matched, positioning Foundation for continued impact; opportunity and need persist in challenged research funding environment -- NEW YORK, Feb. 27, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) announced that with the help of the Parkinson's community, it has completed and surpassed the $50-million Brin Wojcicki Challenge. Longtime Foundation supporters Sergey Brin and Anne Wojcicki have matched more than $53 million in...
NEW YORK, Feb. 20, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation (MJFF) is today announcing the launch of four new funding programs focused on driving forward research toward transformative treatments and a cure for Parkinson's disease (PD). MJFF places a strong emphasis on translational and clinical research, but also supports high-risk/high-reward discovery work to help keep new ideas flowing into the drug development pipeline. The new funding opportunities are open...
